Insogna, Anthony M.

Current Employment Position(s)

Partner

Lawyer Overview

Anthony Insogna has almost 20 years of experience representing clients in intellectual property matters including patent litigation, patent prosecution, strategic counseling, technology transactions, and due diligence. He has prosecuted and enforced worldwide patent portfolios for some of the most successful therapeutics developed by pharmaceutical, biotechnology, and medical device companies. Anthony has significant experience with the patent and FDA laws under the Hatch-Waxman Act, and he regularly handles IP issues attendant to mergers, acquisitions, partnerships, strategic collaborations, licensing, and financing for life sciences companies.

Representative clients include Celgene, MedImmune, Sepracor, Isis Pharmaceuticals, Amgen, AstraZeneca, Amyris Biotechnologies, BioSphere Medical, PTC Therapeutics, Mitsui Ventures, Ambit Biosciences, as well as investment banks and other private equity firms. Anthony's experience includes patent portfolio development and management, patent infringement actions, oppositions, patent interferences, invalidation proceedings, and strategic transactions for products including Clofar®, Clarinex®, Embospheres®, HepaSpheres®, Tyzeka®, Ethyol®, Synagis®, Focalin®, Focalin XR®, Ritalin LA®, Relafen®, Pristiq®, Allegra®, Thalomid® and others, as well as many product candidates currently in clinical trials.

Anthony is Partner-in-Charge of the San Diego Office.

Areas of Practice

• Intellectual Property
• Patent Litigation
• Patent Prosecution
• Biotechnology
• Life Sciences
• Pharmaceuticals

Representative Cases

• Actimis develops patent portfolio for CRTH2 and CCR3 modulators , (2009)
• Ambit Biosciences develops patent portfolio for small molecule kinase inhibitor programs
• Amyris Biotechnologies develops patent portfolio for renewable biofuels
• Bioenvision develops patent portfolios for Clolar® and Modrenal®
• BioSphere develops global patent portfolio for use of microspheres for tissue bulking
• BioSphere develops global patent portfolio related to polyvinyl alcohol microspheres , (2009)
• BioSphere develops patent portfolio for Quadrasphere® / Hepasphere®
• BioSphere establishes global patent portfolio related to microspheres for stem cell delivery
• BioSphere Medical resolves declaratory judgment and patent infringement actions against Artes Medical
• BioSphere purchases assets from RJ Medical, Inc. , (2009)
• Celgene develops patent portfolio for Thalomid® (Thalidomide), IMiDs™ and SelCIDS™
• Celgene establishes global patent portfolio for small molecule pharmaceuticals , (2009)
• Celgene files Hatch-Waxman suit against IntelliPharmaCeutics over Focalin XR® patent , (2009)
• Celgene files patent infringement charges against Actavis and Abrika over generic versions of ADHD drug Focalin XR® , (2009)
• Celgene files patent infringement suit against Barr Labs over generic version of ADHD drug Focalin XR® , (2009)
• Celgene files patent infringement suit against generic drug maker Teva Pharmaceuticals over ADHD drugs , (2009)
• Celgene files patent suit against KV Pharmaceuticals over generic version of Focalin XR® , (2009)
• Celgene licenses to Cambrex certain chiral intermediate chemistries , (2010)
• Celgene licenses to Teva market generic version of Focalin capsules and tablets , (2010)
• Celgene lodges patent infringement charges against Barr Labs over generic version of Ritalin LA® , (2009)
• Celgene pursues patent infringement litigation against Abrika concerning Ritalin LA® , (2009)
• Celgene pursues patent infringement litigation against KV Pharmaceutical concerning Ritalin LA® , (2009)
• Celgene pursues patent infringement litigation against Teva concerning Focalin XR®
• Celgro files patent infringement suit against Cambrex involving enzymatic synthesis of chiral amines , (2010)
• Copley Pharmaceutical successfully defends against Hatch-Waxman challenge to patent for Relafen® anti-inflammatory drug
• Cougar Biotech gets purchased by J & J, including global patent portfolio for prostate cancer treatment , (2009)
• Cougar Biotechnology builds global patent portfolio for prostate cancer treatment
• Daiichi Sankyo acquires generic-drug maker Ranbaxy Laboratories for $4.6 billion
• Esperion establishes patent portfolios for small molecule cholesterol-lowering drugs
• Estee Lauder lodges section 146 action challenging BPAI decision involving sunscreen products
• Idenix establishes patent portfolio related to nucleoside analog antiviral drugs , (2010)
• Indena defends against claims of patent infringement involving dietary supplements , (2009)
• Isis expands patent portfolio related to bicyclic nucleic acids (BNAs) and antisense oligomers containing BNAs
• Isis Pharmaceuticals builds patent portfolio for certain clinical development compounds
• MedImmune establishes patent portfolio for Ethyol® (Amifostine)
• MedImmune establishes patent portfolio for Synagis® and Numax™
• MedImmune expands global patent portfolio, including influenza vaccines , (2009)
• PTC Therapeutics builds patent portfolio for small molecule technology , (2009)
• QOL Medical files patent infringement suit against Fleming & Co. involving cyanocobalamin low viscosity aqueous formulations for intranasal delivery , (2010)
• Sepracor develops patent portfolio directed to isomers and metabolites, including CLARINEX® and ALLEGRA® , (2009)
• Sugen develops patent portfolio for drugs used in cancer treatment
• Sunesis Pharmaceuticals builds patent portfolio for small molecule oncological drugs , (2009)
• Tularik establishes patent portfolio for certain small molecule programs

West Practice Categories

Copyrights, Intellectual Property Law, International Intellectual Property, Patent Litigation, Patents, Technology Licensing, Trade Dress, Trade Secrets, Trademarks

Bar Admissions

• California
• District of Columbia
• New York

Education

• Fordham University
• New York University

Published Works

• Fresh start for biosimilars in 2009?, The Daily Transcript, San Diego's Busniess Daily, 2009
• Biofuels: A (Carbon) Balanced Act, The Daily Transcript, Vol. 123, No. 223, 2008
• CIRM Funding Worth the Cost of Rules, Restrictions?, The Daily Transcript, Vol. 123, No. 208, 2008
• Handle with care, IP rights in developing countries, Patent World Issue #191, 2007
• Five Questions on the New Stem Cell Initiative, California Lawyer, 2005
• States Fund Stem Cell Research, Biotechnology, The National Law Journal, 2005
• A Reinvestigation of the Reactions Occurring upon Photoexcitation of Cyclophexenome in the Presence of Triethylamine, The Journal of Organic Chemistry, Vol. 56, pages 1879-1882., 1991

Address

12265 El Camino Real Suite 200
San Diego, CA 92130-4096

Phones

1.858.314.1130 (Business Phone)

Faxes

1.858.314.1150 (Business Fax)

Emails

Contact Us (Business Email)

Websites

http://www.jonesday.com